A combination of markers, such as fewer CD8 T cells in circulation and a drop in ctDNA burden could predict response to immune checkpoint blockade in patients with NSCLC after the 1 st cycle of treatment [39]. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.